{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-046481","form_type":"8-K","ticker":"KALV","cik":"0001348911","company_name":"KalVista Pharmaceuticals, Inc.","filed_at":"2024-04-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.047690+00:00","generated_at":"2026-06-03T13:37:23.026605+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"KalVista appoints William Fairey to Board; commercial expertise in rare disease","bullets":["William Fairey appointed to Board effective April 18, 2024 as Class III director.","Mr. Fairey previously served as Chief Commercial Officer at MyoKardia and COO at ChemoCentryx.","Initial compensation includes options to purchase 17,000 shares and $42,500 annual cash retainer.","Appointment adds commercial launch experience ahead of planned FDA submission for sebetralstat.","Mr. Fairey is independent under Nasdaq and SEC rules."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-046481","json":"https://secwatch.observer/filing/0000950170-24-046481.json","markdown":"https://secwatch.observer/filing/0000950170-24-046481.md","text":"https://secwatch.observer/filing/0000950170-24-046481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348911/000095017024046481/0000950170-24-046481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348911/000095017024046481/kalv-20240418.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T13:37:23.026605+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6c4c0f3a50","claim":"William Fairey was appointed as Class III Director at KalVista Pharmaceuticals, Inc..","evidence_excerpt":"the Board approved the appointment of William Fairey (“ Mr. Fairey ”) to the Board effective immediately, to serve until his successor is duly elected and qualified","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348911/000095017024046481/0000950170-24-046481-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}